Mounting evidence demonstrates uncontrolled endoplasmic reticulum (ER) stress responses can activate the inflammasome, which generally results in endothelial dysfunction, a major pathogenetic factor of chronic inflammatory diseases such as atherosclerosis. Salvianolic acid B (SalB), produced by Radix Salviae, exerts antioxidative and anti‐inflammatory activities in multiple cell types. However, SalB’s effects on ER stress‐related inflammasome and endothelial dysfunction remain unknown. Here, we showed SalB substantially abrogated ER stress‐induced cell death and reduction in capillary tube formation, with declined intracellular reactive oxygen species (ROS) amounts and restored mitochondrial membrane potential (MMP), as well as increased expression of HO‐1 and SOD2 in bone marrow‐derived endothelial progenitor cells (BM‐EPCs). ER stress suppression by CHOP or caspase‐4 siRNA transfection attenuated the protective effect of SalB. Additionally, SalB alleviated ER stress‐mediated pyroptotic cell death via the suppression of TXNIP/NLRP3 inflammasome, as evidenced by reduced cleavage of caspase‐1 and interleukin‐ (IL‐) 1β and IL‐18 secretion levels. Furthermore, this study provided a mechanistic basis that AMPK/FoxO4/KLF2 and Syndecan‐4/Rac1/ATF2 signaling pathway modulation by SalB substantially prevented BM‐EPCs damage associated with ER stress by decreasing intracellular ROS amounts and inducing NLRP3‐dependent pyroptosis. In summary, our findings identify that ER stress triggered mitochondrial ROS release and NLRP3 generation in BM‐EPCs, while SalB inhibits NLRP3 inflammasome‐mediated pyroptotic cell death by regulating the AMPK/FoxO4/KLF2 and Syndecan‐4/Rac1/ATF2 pathways. The current findings reveal SalB as a potential new candidate for the treatment of atherosclerotic heart disease.
Background: Cancer patients are increasingly affected by chemotherapy‐related cardiac dysfunction. The reported incidence of this condition vary significantly across different studies.Hypothesis: A better comprehensive understanding of chemotherapy‐related cardiac dysfunction incidence in cancer patients is imperative. Therefore, we performed a meta‐analysis to establish the overall incidence of chemotherapy‐related cardiac dysfunction in cancer patients.Methods: We searched articles in PubMed and EMBASE from database inception to May 1, 2023. Studies that reported the incidence of chemotherapy‐related cardiac dysfunction in cancer patients were included.Results: A total of 53 studies involving 35 651 individuals were finally included in the meta‐analysis. The overall pooled incidence of chemotherapy‐related cardiac dysfunction in cancer patients was 63.21 per 1000 person‐years (95% CI: 57.28−69.14). The chemotherapy‐related cardiac dysfunction incidence increased steeply within half a year of cancer chemotherapy. Also, the trend of chemotherapy‐related cardiac dysfunction incidence appeared to have plateaued after a longer duration of follow‐up. In addition, chemotherapy‐related cardiac dysfunction incidence rates are significantly higher among patients with age ≥50 years versus patients with age <50 years (99.96 vs. 34.48 per 1000 person‐years). The incidence rate of cardiac dysfunction was higher among breast cancer patients (72.97 per 1000 person‐years), leukemia patients (65.21 per 1000 person‐years), and lymphoma patients (55.43 per 1000 person‐years).Conclusion: Our meta‐analysis unveiled a definitive overall incidence rate of chemotherapy‐related cardiac dysfunction in cancer patients. In addition, it was found that the risk of developing this condition escalates within the initial 6 months postchemotherapy, subsequently tapering off to become statistically insignificant after a duration of 6 years.
15 February 2017 in International Journal of Molecular Medicine
It has been reported that exogenous hydrogen sulfide (H2S) protects against high glucose (HG)-induced cardiac injury and has a modulatory effect on heat shock protein (HSP) and Akt, which play a cardioprotective role. In this study, we examined whether the HSP90/Akt pathway contributes to the protective effects of exogenous H2S against HG-induced injury to H9c2 cardiac cells. Our results revealed that the exposure of H9c2 cardiac cells to 35 mM glucose (HG) for 1 to 24 h decreased the expression of HSP90 and markedly reduced the expression level of phosphorylated (p)-Akt in a time-dependent manner. Co-exposure of the cells to HG and geldanamycin (GA; an inhibitor of HSP90) aggravated the inhibition of the p-Akt expression level by HG. Of note, treatment of the cells with 400 µM NaHS (a donor of H2S) for 30 min prior to exposure to HG significantly attenuated the HG-induced decrease in the expression levels of both HSP90 and p-Akt, along with inhibition of HG-induced cell injury, as indicated by the increase in cell viability and superoxide dismutase (SOD) activity, and by a decrease in the number of apoptotic cells, reactive oxygen species (ROS) generation, as well as by the decreased dissipation of mitochondrial membrance potential (MMP). Importantly, treatment of the cells with GA or LY294002 (an inhibitor of Akt) prior to exposure to NaHS and HG considerably blocked the cardioprotective effects of NaHS against the HG-induced injury mentioned above. On the whole, the findings of this study demonstrate that the inhibition of the HSP90/Akt pathway may be an important mechanism responsible for HG-induced cardiomyocyte injury. We also provide novel evidence that exogenous H2S protects H9c2 cells against HG-induced injury by activating the HSP90/Akt pathway.
Summary: Aims: Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)‐β/Smad signaling pathway, improves cardiac function and reduces fibrosis. We determined whether these effects were common among the diuretics and whether angiotensin II receptor type 1 (AT1) signaling pathway played a role in these effects.Methods: Heart failure was produced by ligating the left anterior descending coronary artery in adult male Sprague Dawley rats. Two weeks after the ligation, 70 rats were randomly divided into five groups: sham‐operated group, control group, valsartan group (80 mg/kg/d), hydrochlorothiazide group (12.5 mg/kg/d) and furosemide group (20 mg/kg/d). In addition, neonatal rat ventricular fibroblasts were treated with angiotensin II.Results: After eight‐week drug treatment, hydrochlorothiazide group and valsartan group but not furosemide group had improved cardiac function (ejection fraction was 49.4±2.1%, 49.5±1.8% and 39.9±1.9%, respectively, compared with 40.1±2.2% in control group), reduced cardiac interstitial fibrosis and collagen volume fraction (9.7±1.2%, 10.0±1.3% and 14.1±0.8%, respectively, compared with 15.9±1.1% in control group), and decreased expression of AT1, TGF‐β and Smad2 in the cardiac tissues. In addition, hydrochlorothiazide reduced plasma angiotensin II and aldosterone levels. Furthermore, hydrochlorothiazide inhibited angiotensin II‐induced TGF‐β1 and Smad2 protein expression in the neonatal rat ventricular fibroblasts.Conclusions: Our study indicates that the cardiac function and remodeling improvement after ischemic heart failure may not be common among the diuretics. Hydrochlorothiazide may reduce the left ventricular wall stress and angiotensin II signaling pathway to provide these beneficial effects.